Chatelut E - Search Results

1

Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: pharmacokinetic and pharmacodynamic evaluation.

Guichard S, Montazeri A, Chatelut E, Hennebelle I, Bugat R, Canal P. Guichard S, et al. Among authors: chatelut e. Clin Cancer Res. 2001 Oct;7(10):3222-8. Clin Cancer Res. 2001. PMID: 11595718

2

Pharmacokinetic modeling of plasma and cerebrospinal fluid methotrexate after high-dose intravenous infusion in children.

Chatelut E, Roche H, Plusquellec Y, Peyrille F, De Biasi J, Pujol A, Canal P, Houin G. Chatelut E, et al. J Pharm Sci. 1991 Aug;80(8):730-4. doi: 10.1002/jps.2600800804. J Pharm Sci. 1991. PMID: 1791530

3

Teniposide and cisplatin given by intraperitoneal administration: preclinical and phase I/pharmacokinetic studies.

Chatelut E, de Forni M, Canal P, Chevreau C, Roche H, Plusquellec Y, Johnson NP, Houin G, Bugat R. Chatelut E, et al. Ann Oncol. 1991 Mar;2(3):217-21. doi: 10.1093/oxfordjournals.annonc.a057910. Ann Oncol. 1991. PMID: 2043492 Free article. Clinical Trial.

4

Pharmacokinetics and toxicity of two modalities of etoposide infusion in metastatic non-small-cell lung carcinoma.

Chatelut E, Chevreau C, Blancy E, Lequellec A, Canal P, Roche H, Houin G, Bugat R. Chatelut E, et al. Cancer Chemother Pharmacol. 1990;26(5):365-8. doi: 10.1007/BF02897295. Cancer Chemother Pharmacol. 1990. PMID: 2170043

5

Clinical and pharmacokinetic study of intraperitoneal cisplatin at two dose levels: 100 mg/m2 alone or 200 mg/m2 with i.v. sodium thiosulfate.

Canal P, de Forni M, Chatelut E, Chevreau C, Johnson NP, Houin G, Bugat R. Canal P, et al. Among authors: chatelut e. Acta Med Austriaca. 1989;16(3-4):84-6. Acta Med Austriaca. 1989. PMID: 2609919

6

[Comparison of the pharmacokinetics of cisplatin administered by the intraperitoneal route in 2 dosages: 100 and 200 mg/m2].

Canal P, Chatelut E, De Forni M, Chevreau C, Johnson N, Houin G, Bugat R. Canal P, et al. Among authors: chatelut e. Bull Cancer. 1989;76(8):879-82. Bull Cancer. 1989. PMID: 2620116 French. No abstract available.

7

[Phase I trial and pharmacokinetics of VM 26 combined with cisplatin administered by the intraperitoneal route without mixing time].

Chatelut E, Canal P, De Forni M, Chevreau C, Houin G, Bugat R. Chatelut E, et al. Bull Cancer. 1989;76(8):893-6. Bull Cancer. 1989. PMID: 2620120 French. No abstract available.

8

Phase I/pharmacokinetic study of intraperitoneal teniposide (VM 26).

Canal P, Bugat R, Chatelut E, Pinel MC, Houin G, Plusquellec Y, Carton M. Canal P, et al. Among authors: chatelut e. Eur J Cancer Clin Oncol. 1989 May;25(5):815-20. doi: 10.1016/0277-5379(89)90126-0. Eur J Cancer Clin Oncol. 1989. PMID: 2737218

9

A pharmacokinetic model for intraperitoneal administration of drugs: application to teniposide in humans.

Canal P, Plusquellec Y, Chatelut E, Bugat R, De Biasi J, Houin G. Canal P, et al. Among authors: chatelut e. J Pharm Sci. 1989 May;78(5):389-92. doi: 10.1002/jps.2600780509. J Pharm Sci. 1989. PMID: 2746477

10

[Relations between hematological toxicity and total and free plasma levels of etoposide in daily oral administration].

Lavit M, Chevreau C, Chatelut E, De Fenin V, Lochon I, Houin G, Bugat R, Canal P. Lavit M, et al. Among authors: chatelut e. Bull Cancer. 1995 Aug;82(8):660-4. Bull Cancer. 1995. PMID: 7492822 French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

244 results

Search Page

Filters